Doravirin

What is Doravirin?

Doravirin is an antiretroviral medication used as part of a combination regimen for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It belongs to a class of drugs known as non-nucleoside reverse transcriptase inhibitors, or NNRTIs. Marketed under the brand name Pifeltro, Doravirin works by targeting a specific enzyme crucial for the HIV life cycle, thereby helping to reduce the viral load in the body and improve the immune system's function. This medication is a vital component of modern HIV treatment strategies, offering an effective option for many patients.

First approved by regulatory bodies, Doravirin has become an important tool in the ongoing battle against HIV. It is typically prescribed to adults and adolescents aged 12 years and older, weighing at least 35 kg, who are either starting their first HIV regimen (treatment-naïve) or are switching from another regimen due to tolerability or safety concerns, provided they have no history of virologic failure on a doravirin-containing regimen.

How Does it Work?

The mechanism of action of Doravirin is centered on its role as a non-nucleoside reverse transcriptase inhibitor. HIV, a retrovirus, uses an enzyme called reverse transcriptase to convert its RNA into DNA, which it then integrates into the host cell's genome. This step is essential for the virus to replicate and spread throughout the body. Doravirin specifically binds to and inhibits this reverse transcriptase enzyme. Unlike nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs like Doravirin do not require intracellular phosphorylation to be active.

By directly interfering with the reverse transcriptase enzyme, Doravirin prevents the virus from converting its RNA into DNA. This effectively halts the viral replication process, reducing the amount of HIV in the blood (viral load) and allowing the immune system to recover. Its highly selective binding to the reverse transcriptase enzyme ensures potent antiviral activity against HIV-1 while minimizing impact on human cellular enzymes, contributing to its generally favorable tolerability profile.

Medical Uses

Doravirin is approved for the treatment of HIV-1 infection in adults and adolescents who are 12 years of age and older and weigh at least 35 kg. It is indicated for use in combination with other antiretroviral agents. The primary scenarios for its use include:

• Treatment-Naïve Patients: Individuals who are starting antiretroviral therapy for the first time. Doravirin provides a potent and well-tolerated option as part of their initial regimen.
• Treatment-Experienced Patients (Switch Therapy): Patients who are currently on another antiretroviral regimen but are switching to Doravirin due to issues like tolerability, safety concerns, or drug interactions, provided they have no history of virologic failure on a doravirin-containing regimen.

It is crucial to understand that Doravirin, like all HIV medications, is not a cure for HIV-1 infection. It is part of a lifelong antiretroviral therapy (ART) regimen designed to manage the infection, suppress the viral load to undetectable levels, improve immune function, and prevent disease progression. Doravirin is also available in fixed-dose combination tablets (e.g., Delstrigo, which combines doravirin with lamivudine and tenofovir disoproxil fumarate) to simplify dosing and improve adherence.

Dosage

The recommended doravirin dosage for adults and adolescents (aged 12 years and older and weighing at least 35 kg) is one 100 mg tablet taken orally once daily. Doravirin can be taken with or without food. It is vital to adhere strictly to the prescribed dosage and schedule to maintain effective drug levels in the body and prevent the development of drug resistance.

If a dose is missed, it should be taken as soon as the patient remembers, unless it is closer to the time of the next dose. In that case, the missed dose should be skipped, and the patient should continue with their regular dosing schedule. Double doses should not be taken to make up for a missed dose.

No dosage adjustment is required for patients with mild, moderate, or severe renal impairment, or for those with mild or moderate hepatic impairment. However, Doravirin has not been studied in patients with severe hepatic impairment, and caution is advised in this population.

Side Effects

Like all medications, Doravirin can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and tend to resolve over time. Common doravirin side effects include:

• Nausea
• Diarrhea
• Headache
• Fatigue
• Dizziness
• Abnormal dreams or insomnia

Less common but potentially more serious side effects may include:

• Hypersensitivity Reactions: Although rare, severe allergic reactions can occur. Patients should seek immediate medical attention if they experience rash, fever, blistering, or swelling.
• Liver Problems: Cases of liver toxicity have been reported. Symptoms may include yellowing of the skin or eyes (jaundice), dark urine, light-colored stools, or pain in the upper right side of the abdomen.
• Psychiatric Effects: Some patients may experience mood changes, depression, anxiety, or suicidal thoughts. It is important to report any new or worsening psychiatric symptoms to a healthcare provider.

Patients should always inform their healthcare provider about any unusual or persistent side effects they experience while taking Doravirin. Regular monitoring by a doctor is essential to manage potential side effects.

Drug Interactions

Doravirin is primarily metabolized by the cytochrome P450 3A (CYP3A) enzyme system. Therefore, co-administration with drugs that are strong inducers of CYP3A can significantly decrease Doravirin plasma concentrations, potentially leading to a loss of therapeutic effect and the development of resistance. Conversely, strong inhibitors of CYP3A are not expected to have a clinically significant effect on Doravirin exposure.

Key drug interactions to be aware of include:

• Strong CYP3A Inducers: Co-administration with drugs like rifampin (for tuberculosis), carbamazepine, phenytoin, phenobarbital (anticonvulsants), or St. John's wort (herbal supplement) is contraindicated or not recommended due to the risk of reduced Doravirin efficacy.
• Other Antiretrovirals: Care must be taken when combining Doravirin with certain other antiretroviral medications, especially those that also interact with CYP3A or have overlapping toxicities.
• Antacids: Antacids generally do not significantly affect Doravirin absorption, but it's always best to separate administration if possible or follow specific guidance.

Patients must inform their healthcare provider about all prescription drugs, over-the-counter medications, and herbal supplements they are taking to avoid potentially harmful drug interactions.

FAQ

Q: Is Doravirin a cure for HIV?

A: No, Doravirin is not a cure for HIV-1 infection. It is an antiretroviral medication that helps to manage the virus, suppress its replication, and improve the immune system's health, but it does not eliminate HIV from the body.

Q: Can I take Doravirin if I'm pregnant?

A: The use of Doravirin during pregnancy should be discussed with a healthcare provider. They will weigh the potential benefits against any risks to the mother and the unborn baby. A pregnancy registry is available for monitoring outcomes.

Q: How quickly does Doravirin reduce the viral load?

A: Doravirin, as part of an effective antiretroviral regimen, typically begins to reduce the viral load within weeks. With consistent adherence, many patients can achieve an undetectable viral load within a few months.

Q: What should I do if I miss a dose of Doravirin?

A: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

Products containing Doravirin are available through trusted online pharmacies. You can browse Doravirin-based medications at ShipperVIP or Medicenter.

Summary

Doravirin stands as an important and effective non-nucleoside reverse transcriptase inhibitor (NNRTI) in the arsenal against HIV-1 infection. As a key component of combination antiretroviral therapy, it works by specifically inhibiting the reverse transcriptase enzyme, thereby preventing the virus from replicating and helping to reduce the viral load. Whether used in treatment-naïve individuals or as a switch option for experienced patients, Doravirin, often known by its brand name Pifeltro, offers a generally well-tolerated profile with a convenient once-daily dosing schedule.

While not a cure, this HIV medication plays a critical role in managing the infection, improving quality of life, and preventing disease progression. Patients should be aware of potential side effects and significant drug interactions, particularly with strong CYP3A inducers. Consistent adherence to the prescribed regimen and regular consultation with a healthcare provider are paramount to achieving optimal outcomes and ensuring safe and effective HIV treatment with Doravirin.